studies

1298A AASLD ABSTRACTS HEPATOLOGY, October, 2015
2238
Non-alcoholic fatty liver disease: assessment of intestinal
microbiota and metabolites
Hannah Da Silva 1,2 , Anastasia Teterina 1 , Bianca M. Arendt 1 ,
Marialena Mouzaki 3 , Sandra E. Fischer 4 , Scott Fung 5 , Johane P.
Allard 5 ; 1 Gastroenterology, Toronto General Hospital, Toronto,
ON, Canada; 2 Department of Nutritional Sciences, University of
Toronto, Toronto, ON, Canada; 3 GI/Hepatology/Nutrition, Hospital
for Sick Children, Toronto, ON, Canada; 4 Pathology, University
Health Network, Toronto, ON, Canada; 5 Medicine, Toronto
General Hospital, Toronto, ON, Canada
Background: Intestinal microbiota (IM) may contribute to non-alcoholic
fatty liver disease (NAFLD) through products of bacterial
metabolism. This study aimed to characterize the bacterial
products present in serum and stool of NAFLD patients and
HC and to examine the relationship between these products
and IM. Methods: This was a prospective, cross-sectional
study. Fecal and serum metabolite profiles of 39 patients with
biopsy-proven NAFLD and 28 living liver donors as HC were
examined using nuclear magnetic resonance spectroscopy.
Metabolic profiles included 11 fecal and 9 serum bacterial
products. In a subset of 29 NAFLD and 16 HC, IM composition
was assessed. Clinical, biochemical, and anthropometric
data were also collected. Quantitative real-time polymerase
chain reaction was used to measure total bacterial counts,
Firmicutes:Bacteroidetes ratio, Bacteroidetes, C. leptum, C.
coccoides, Bifidobacteria, E. coli and Archaea in stool. Continuous
variables were non-normal and described as median
(Q1, Q3). Groups were compared using Wilcoxon rank-sum
tests. Spearman correlation coefficients were used to examine
association between IM and bacterial products. Results:
NAFLD patients were older than HC with higher BMI, liver
enzymes (AST, ALT), insulin resistance (HOMA-IR), hemoglobin
A1c, and blood triglycerides (p